Pursuant to the Company’s Code of Conduct to Regulate, Monitor and Report Trading by Insiders, formulated and adopted under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, Unichem Laboratories has informed that the Trading Window for dealing in shares of the Company will be closed for Designated Persons, Directors, Insiders and their Immediate Relatives from Monday, 23rd September 2024 in view of the meeting of the Board of Directors of the Company scheduled to be held on Monday, 30th September 2024 to consider, integration and consolidation of the generics formulations business in the US market of Bayshore Pharmaceuticals LLC (wholly owned subsidiary of Company’s holding company, Ipca Laboratories) into Unichem Pharmaceuticals (USA) Inc. (company’s wholly owned subsidiary) so as to consolidate all the Ipca Group’s USA generics formulations business under one entity. The window closure will continue from 1st October 2024 till 48 hours after declaration of financial results of the Company for the quarter and half year ended 30th September 2024 for Designated Persons, Directors, Insiders and their Immediate Relatives.
The above information is a part of company’s filings submitted to BSE.
